Basik Mark, Mousses Spyro, Trent Jeffrey
Translational Genomics Research Institute, Gaithersburg, MD, USA.
Biotechniques. 2003 Sep;35(3):580-2, 584, 586 passim. doi: 10.2144/03353dd01.
New technologies have greatly increased the scientist's ability to investigate complex molecular interactions that occur in cancer development and to identify genetic alterations and drug targets. However, these new capabilities have not accelerated drug development efforts; rather, they may be contributing to increased research and development costs because the large number of new drug targets discovered through genomics need to be investigated in great detail to characterize their putative functional involvement in the disease process. One solution to this bottleneck in functional analysis is the use of high-throughput technologies to produce efficient processes that can rapidly handle the large flood of information at every stage of disease. This review examines the use of new and emerging DNA, tissue, and live-cell transfection microarray technologies that can be used to discover, validate, and translate information resulting from the completion of the Human Genome Project.
新技术极大地提高了科学家研究癌症发展过程中复杂分子相互作用以及识别基因改变和药物靶点的能力。然而，这些新能力并未加速药物研发进程；相反，它们可能导致研发成本增加，因为通过基因组学发现的大量新药物靶点需要进行详细研究，以确定其在疾病过程中假定的功能作用。解决功能分析这一瓶颈的一个办法是使用高通量技术来产生高效的流程，以便在疾病的各个阶段迅速处理大量信息。本综述探讨了新型及新兴的DNA、组织和活细胞转染微阵列技术的应用，这些技术可用于发现、验证以及转化人类基因组计划完成后所产生的信息。
